GBM AGILE TRIAL

Brief description of study

Glioblastoma adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. Its goals are to identify effective therapies for glioblastoma and match effective therapies with patient subtypes. Bayesian response adaptive randomization is used within subtypes of the disease to assign participants to Arms based on their performance. The primary endpoint is overall survival (OS).


Clinical Study Identifier: s19-00633
ClinicalTrials.gov Identifier: NCT03970447
Principal Investigator: Erik P. Sulman.
Other Investigators: Minerva A Utate, Maria Del Pilar Guillermo Prieto Eibl, Alexandra M. Miller, Alexandra Gewirtz, Jessica Goggin, Ryan C Mitchell, Lynda Julie Boulio-Castillo, Jennifer H Fisher, Caitlin Elizabeth Ryan, Marissa Barbaro, Joshua S. Silverman, Jonathan Tzu-l Yang, Jose Ricardo McFaline Figueroa.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.